CyFlow™ HLA-DR PE
| Antigen: | HLA-DR |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | L243 |
| Emission Maximum: | 576 nm |
| Excitation Maximum: | 496 nm, 565 nm |
| Field of Interest: | MHC |
| Format/Fluorochrome: | PE |
| Isotype: | IgG2a |
| Laser: | Blue , Green, Yellow |
| Regulatory Status: | CE IVD |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | CR183597 |
CE IVD
| Concentration Unit | µg/mL |
| Concentration | 60 |
| Quantity | 100 tests |
| Volume | 1.0 mL |
| Immunogen | Human B lymphocytes |
| Background Information | HLA-DR is a member of MHC class II glycoproteins which bind intracellularly processed peptides and present them to the Th cells. HLA-DR is composed of 36 kDa α chain and 27 kDa β chain, both anchored in the plasma membrane. Together with other MHC II molecules HLA-DR plays a central role in the immune system. |
| Antigen Distribution | HLA-DR is a member of MHC class II glycoproteins which bind intracellularly processed peptides and present them to the Th cells. HLA-DR is composed of 36 kDa α chain and 27 kDa β chain, both anchored in the plasma membrane. Together with other MHC II molecules HLA-DR plays a central role in the immune system. |
| Usage | CE IVD usage Placeholder |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M: Triggering of HLA‑DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ. 1997 May; 8(5):581‑8. < PMID: 9149909 > | Cantin R, Martin G, Tremblay MJ: A novel virus capture assay reveals a differential acquisition of host HLA‑DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol. 2001 Dec; 82(12):2979‑87. < PMID: 11714974 > | Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL: Zwitterionic polysaccharides stimulate T cells by MHC class II‑dependent interactions. J Immunol. 2002 Dec 1; 169(11):6149‑53. < PMID: 12444118 > | Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W: Lipid raft‑dependent and ‑independent signaling through HLA‑DR molecules. J Biol Chem. 2003 Feb 28; 278(9):7099‑107. < PMID: 12499388 > | Muczynski KA, Ekle DM, Coder DM, Anderson SK: Normal human kidney HLA‑DR‑expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol. 2003 May; 14(5):1336‑48. < PMID: 12707403 > | De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E: MHC class II stabilization at the surface of human dendritic cells is the result of maturation‑dependent MARCH I down‑regulation. Proc Natl Acad Sci USA. 2008 Mar 4; 105(9):3491‑6. < PMID: 18305173 > | Swiatek-de Lange M, Rist W, Stahl HF, Weith A, Lenter MC: Comment on "MHC class II expression identifies functionally distinct human regulatory T cells". J Immunol. 2008 Mar 15; 180(6):3625. < PMID: 18322165 > | Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLA‑DR can elicit homotypic adhesion followed by lysosome‑mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug; 119(8):2143‑59. < PMID: 19620786 >